Motility News

Mytesi, the only anti-diarrheal approved by the FDA for treating noninfectious diarrhea in adults with HIV/AIDS, generated significant long-term improvement in patients with chronic HIV-related diarrhea, according to data presented at the International AIDS Society Conference on HIV Science.

IW-3718, a novel formulation of bile acid sequestrant, significantly reduced heartburn severity in patients with uncontrolled gastroesophageal reflux disease, or GERD, according to phase 2b clinical trial results published in a press release.

Researchers report they found “no convincing evidence” of an association between the use of proton pump inhibitors and risk for dementia in a new study, which a press release from the AGA said, “puts these claims to rest.”

Chronic use of cannabinoid derivatives led to a significant increase in cannabinoid hyperemesis syndrome, characterized by episodes of severe nausea and cyclical vomiting, the symptoms of which improve with cannabis cessation, as well as cannabinoid dependency.

Researchers found a significant association between long-term use of proton pump inhibitors and risk for death in an observational study of U.S. veterans.

Opioid users in the U.S. are increasingly abusing the over-the-counter anti-diarrheal drug loperamide, commonly sold under the trade name Imodium, following the restriction of medications containing hydrocodone in response to the opioid epidemic.

The first patients enrolled in the LESS GERD trial have been implanted with the EndoStim device, a minimally invasive implant that uses neurostimulation to normalize esophageal function and provide long-term reflux control, the manufacturer announced.

Researchers found no association between the use of proton pump inhibitors and the risk for mild cognitive impairment, dementia and Alzheimer’s disease in a recent observational, longitudinal study.

The FDA has accepted Synergy Pharmaceuticals’ supplemental new drug application to add constipation-predominant irritable bowel syndrome as an indication for Trulance, the company announced.

CHICAGO — FDgard, a medical food containing caraway oil/l-Menthol designed to help manage functional dyspepsia, showed symptom reduction and relief in patients with functional dyspepsia within 24 hours, according to findings presented at Digestive Disease Week.